Literature DB >> 17875049

Cardiovascular risk in chronic obstructive pulmonary disease.

John D Maclay1, David A McAllister, William Macnee.   

Abstract

Cardiovascular disease (CVD) contributes significantly to morbidity and mortality in COPD. There is a high prevalence of traditional risk factors in this patient group including smoking, sedentary behaviour and low socio-economic class. However, large studies have shown that airflow limitation is an independent risk factor for CVD. Therefore there may be a 'COPD effect' that contributes to CVD in this condition, adding to the body of evidence that COPD has important systemic consequences, as well as being a lung disease. In this article, we review the evidence for CVD in COPD. Next, we examine systemic factors present in COPD, and link these to the pathogenesis of atherosclerosis, including inflammation, oxidative stress and hypoxia. Finally, we review those studies that have investigated therapeutic interventions in COPD that may modify cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17875049     DOI: 10.1111/j.1440-1843.2007.01136.x

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  40 in total

1.  Chronic obstructive pulmonary disease: a view from the NHLBI.

Authors:  Antonello Punturieri; Thomas L Croxton; Gail G Weinmann; James P Kiley
Journal:  Am J Respir Crit Care Med       Date:  2008-09-01       Impact factor: 21.405

2.  Risk of atrial fibrillation, stroke, and death after radiofrequency catheter ablation of typical atrial flutter.

Authors:  Javier García Seara; Sergio Raposeiras Roubin; Francisco Gude Sampedro; Vanessa Balboa Barreiro; José Martínez Sande; Moisés Rodriguez Mañero; Pilar Cabans Grandio; Belen Alvarez; José González Juanatey
Journal:  Clin Res Cardiol       Date:  2014-02-25       Impact factor: 5.460

3.  The Effects of Statins on Pulmonary Artery Pressure in Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.

Authors:  Anahita Arian; Sayyed Gholamreza Mortazavi Moghadam; Toba Kazemi; Morteza Hajihosseini
Journal:  J Res Pharm Pract       Date:  2017 Jan-Mar

4.  Evaluation of high-sensitivity serum CRP levels compared to markers of airway inflammation and allergy as predictors of methacholine bronchial hyper-responsiveness in children.

Authors:  Galit Livnat; Ronen Bar Yoseph; Vered Nir; Fahed Hakim; Mordechai Yigla; Lea Bentur
Journal:  Lung       Date:  2014-10-21       Impact factor: 2.584

Review 5.  Comparative United States autoimmune disease rates for 2010-2016 by sex, geographic region, and race.

Authors:  Melissa H Roberts; Esther Erdei
Journal:  Autoimmun Rev       Date:  2019-11-14       Impact factor: 9.754

6.  Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

Authors:  Nathaniel M Hawkins; Zhen Huang; Karen S Pieper; Scott D Solomon; Lars Kober; Eric J Velazquez; Karl Swedberg; Marc A Pfeffer; John J V McMurray; Aldo P Maggioni
Journal:  Eur J Heart Fail       Date:  2009-01-27       Impact factor: 15.534

Review 7.  Heart-lung interaction via infection.

Authors:  Alison Morris
Journal:  Ann Am Thorac Soc       Date:  2014-01

8.  Emphysema is associated with increased inflammation in lungs of atherosclerosis-prone mice by cigarette smoke: implications in comorbidities of COPD.

Authors:  Gnanapragasam Arunachalam; Isaac K Sundar; Jae-Woong Hwang; Hongwei Yao; Irfan Rahman
Journal:  J Inflamm (Lond)       Date:  2010-07-22       Impact factor: 4.981

9.  Metabolic syndrome and associated factors in people with chronic obstructive pulmonary disease.

Authors:  Soo Kyung Park; Janet L Larson
Journal:  West J Nurs Res       Date:  2013-11-29       Impact factor: 1.967

10.  PLAUR polymorphisms and lung function in UK smokers.

Authors:  Ceri E Stewart; Ian P Hall; Stuart G Parker; Miriam F Moffat; Andrew J Wardlaw; Martin J Connolly; Charlotte Ruse; Ian Sayers
Journal:  BMC Med Genet       Date:  2009-10-31       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.